Novartis data at ACTRIMS-ECTRIMS highlight the strength of leading multiple sclerosis (MS) portfolio with life-changing therapies for people across the MS spectrum

Ads

You May Also Like

XBiotech Highlights Third Quarter Developments for 2018

Company Provides Updated Overview including on its Clinical and Discovery Pipeline as well as ...

VBI Vaccines Announces Results of Annual General Meeting

CAMBRIDGE, Mass., May 25, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) ("VBI" or ...

Aptevo Therapeutics Reports Third Quarter 2018 Financial Results

Achieves 132% Increase in IXINITY® Quarterly Net Revenue Year-Over-Year More than Doubles Year-to-Date IXINITY ...